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E-mail address: carlospu77@gmail.com (C.J. RodrigTungstate counteracts diabetes and obesity in animal models, but its molecular mechanisms remain
elusive. Our Saccharomyces cerevisiae-based approach has found that tungstate alleviated the
growth defect induced by nutrient stress and enhanced the activation of the GCN pathway. Tung-
state relieved the sensitivity to starvation of a gcn2-507 yeast hypomorphic mutant, indicating that
tungstate modulated the GCN pathway downstream of Gcn2p. Interestingly, tungstate inhibited
Glc7p and PP1 phosphatase activity, both negative regulators of the GCN pathway in yeast and
humans, respectively. Accordingly, overexpression of a dominant-negative Glc7p mutant in yeast
mimicked tungstate effects. Therefore tungstate alleviates nutrient stress in yeast by in vivo inhibi-
tion of Glc7p. These data uncover a potential role for tungstate in the treatment of PP1 and GCN
related diseases.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The phosphorylation of the eukaryotic initiation factor 2-a sub-
unit (eIF2a) through the General Control of Nutrients (GCN) path-
way occurs in response to amino acid deprivation in yeast and
mammals [1]. In yeast, Gcn2p protein kinase is the responsible of
phosphorylating eIF2a at serine 51 [2]. This phosphorylation
diminishes general protein synthesis and enhances the speciﬁc
transcription of genes involved in amino acid biosynthesis. Trans-
lational regulation of GCN4 is mediated by four short open reading
frames located in its 50-untranslated region [2]. This peculiarity
allows the GCN4 mRNA being translated in deprivation conditions
and thus stimulating transcription of genes entitled to overcome
the starvation state, like HIS4 [3].
FK506 is an immunosuppressant used to prevent allograft rejec-
tion after organ transplantation. Through calcineurin inhibition it
impedes transcription of genes involved in immune response [4].
FK506 impairs Saccharomyces cerevisiae cell growth by inhibiting
tryptophan, histidine and leucine import in strains auxotrophic
for these amino acids [5,6]. Previous evidences indicate that
tryptophan starvation is mainly responsible for this growth defectchemical Societies. Published by E
Biomedicine (IRB Barcelona),
uez-Hernandez).[7]. Other inductor of amino acid deprivation in yeast is
3-amino-1,2,4-triazole (3AT), an inhibitor of histidine biosynthesis
[8] that causes scarcity of this amino acid.
Stimuli other than amino acid have been reported to trigger the
GCN pathway, such as purine starvation [9], glucose limitation,
ethanol [10], DNA damage [3], high salinity [11,12], rapamycin
[13–15] and volatile anesthetics [16]. In mammals, the GCN path-
way is triggered by UV irradiation, proteasome inhibition, mis-
folded protein in the ER, double-stranded RNA, haem deprivation,
as well as oxidative and heat stresses in erythroid tissues
(reviewed in [17]). Many lines of evidence linking the GCN path-
way and human disease have been described. Mutations in the
Gcn2p mammalian orthologue, PERK, causes the Wolcott–Rallison
syndrome, a rare childhood diabetic disorder [18–20]. Accordingly
PERK-deﬁcient mice develop hyperglycemia and b-cell death
[21,22]. Furthermore, mutant mice with non-phosphorylatable
eIF2a (Ser51Ala) mutant die because of hypoglycemia [22].
Recently, the relevance of eIF2a for insulin production in adapta-
tion to a high-fat diet has been underscored [23]. Other disease
conditions, like tumor progression [24], connective tissue diseases
[25], drug resistance [26], aging and sleep disorders [27] have been
recently related to translational control.
The status of eIF2a phosphorylation is negatively regulated by
phosphatases. In yeast, the main eIF2a phosphatase is Glc7p
[28], an orthologue of the catalytic subunit of the mammalianlsevier B.V. All rights reserved.
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Glc7p. This phosphatase is required for lots of cellular functions
like cell cycle progression [30], glycogen synthesis [31], glucose
repression [32], ionic homeostasis [33] or DNA replication [34].
Accordingly, mammalian PP1 plays also a pivotal role in cell phys-
iology, as is reﬂected by its large variety of substrates and functions
[35].
Tungstate (WO24 ) is a phosphatase inhibitor [36–39] with anti-
diabetic properties. This substance exhibits an excellent therapeu-
tic proﬁle, both in long- and short-term treatments [40,41]. When
administered orally, sodium tungstate normalizes glycemia in
many animal models of type 1 and 2 diabetes [41–44]. It also in-
creases the total amount and translocation of GLUT4 transporter
in muscle [45] and restores the hepatic metabolism of glucose in
streptozotocin-induced diabetic rats [43,44]. In streptozotocin-
treated neonatal rats tungstate administration stimulates insulin
secretion [42,46] and regenerates b-cell population [42]. This com-
pound also reduces signiﬁcantly weight gain and adiposity by
increasing energy dissipation and the fatty acid oxidation rate in
an obese rats model system [47]. Unfortunately, the molecular
mechanisms of tungstate action are not yet deﬁned.
The budding yeast S. cerevisiae is being widely used as a model
for investigating fundamental processes relevant to all living
organisms. The genetic tractability of budding yeast, its ease of
manipulation and the wealth of functional genomics tools avail-
able in this organismmakes it an attractive model for investigating
drug mechanisms of action. By conducting a phenotypic screening
we found that tungstate relieved nutrient stress inS. cerevisiae. This
effect seemed to be mediated by the inhibition of the eIF2a phos-
phatase Glc7p. This inhibition also occurred in vitro in the Glc7p
mammalian orthologue, PP1. We propose that tungstate depen-
dent regulation of the GCN pathway might be relevant for the
anti-diabetic properties of tungstate thus uncovering potential
new applications for this compound in chemotherapy.
2. Materials and methods
2.1. Yeast strains and plasmids
Yeast strains are described in Table 1. Yeast cells were trans-
formed by standard procedures [48]. The plasmid p180, expressing
a GCN4-lacZ fusion including the entire GCN4 50-non-coding region
with four upstream open reading frames inserted into YCp50, a low
copy-number plasmid marked with URA3, has been described
previously [10]. The HIS4-lacZ p377 reporter plasmid containing
the HIS4 promoter, upregulated by Gcn4p, and marked with LEU2
has also been reported [49]. The plasmid p27-1, harboring a trun-
cated version of GLC7 (glc7D209-312) into the high-copy-number
URA3 plasmid YEp24 has been described previously [28].
2.2. Yeast growth assays
Standard methods for yeast culture and manipulations were
used [50]. Synthetic medium (SD) contained 2% glucose, 0.67%
yeast nitrogen base without amino acids (Pronadisa), and the ami-
no acids, purine and pyrimidine bases required by the strains ofTable 1
Yeast strains.
Name Genotype Ref.
H1402 MATa leu2-3112 ura3-52 ino1 HIS4-lacZ [28]
gcn2-507 H1402 gcn2-507 [28]
Dgcn2 H1402 gcn2::LEU2 [28]
w303.1a MATa ade2-1 can1-100 his3-11,15 leu2-3112 trp1-1 ura3-1
Dcnb1 w303.1a cnb1::LEU2 [53]interest. YPD medium contained 2% glucose, 2% peptone and 1%
yeast extract. Sodium tungstate (Merck) was dissolved in water
and diluted in YPD at the corresponding doses. FK506 was kindly
provided by Astellas Pharma, dissolved in ethanol and diluted in
YPD at the corresponding doses.
For analysis of cell growth by drop test, cells growing logarith-
mically in liquid YPD medium were 10-fold serially diluted, and
volumes of around 3 ll were dropped with a stainless steel replica-
tor (Sigma) on solid plates containing 2% Bacto-Agar (Pronadisa)
and YPD medium with the corresponding doses of FK506 and/or
tungstate as indicated. Growth was recorded after 2–5 days in all
cases.
2.3. Galactosidase assays
Yeast cells transformed with the appropriate reporter plasmids
were grown selectively in SD medium and then diluted in YPD.
Exponential cultures were treated with FK506 and/or tungstate
as indicated. b-Galactosidase activity was determined at the indi-
cated times as described [51] and represented as b-Galactosidase
activity units. Data are the mean ± S.E. from three independent
transformants, each measured in triplicate.
2.4. Immunoblotting
Yeast strains were grown in liquid YPD medium to mid-log
phase and then treated with the corresponding doses of FK506
and/or tungstate as indicated. After treatment, equal numbers of
cells were collected by centrifugation and resuspended in alkaline
Laemmli buffer. Samples were boiled for 5 min and soluble
extracts was recovered after centrifugation. 20 lg of total cellular
protein was subjected to SDS–polyacrylamide gel electrophoresis
and transferred to nitrocellulose (Hybond™, Amersham Biosci-
ences) or PVDF (Immobilon-P; Millipore) ﬁlters. Uniform gel load-
ing was conﬁrmed by Ponceau S staining of membranes after
transfer. Phosphorylated eIF2a was detected with an antiphos-
pho-eIF2a antibody (Ser51) from New England Biolabs. Immuno-
complexes were visualized by enhanced chemiluminescence
detection (Amersham) using a HRP-conjugated goat anti-rabbit
IgG (Amersham). The ﬁgures show an experiment representative
of at least two independent ones with essentially identical results.
2.5. Expression of recombinant proteins in Escherichia coli
E. coli DH5a transformants harboring the GST fusion were
grown in 500 ml of LB/ampicillin, supplemented with 0.5 mM
MnCl2. Transformants were grown at 37 C until the absorbance
at 600 nm reached a value of about 0.3. Isopropyl-1-thio-b-
D-galactopyranoside was then added to a concentration of
0.1 mM, and cultures were grown overnight at 25 C. Cells were
harvested and resuspended in 20 ml of sonication buffer (50 mM
Tris–HCl, pH 7.6, 0.2 mM EGTA, 150 mM NaCl, 10% glycerol, 0.1%
Triton X-100, 2 mM dithiothreitol, 2 mM MnCl2, 2 mM phenyl-
methylsulfonyl ﬂuoride, and complete protease inhibitor mixture
(Roche Applied Science)). Cells were disrupted by sonication, and
the fusion proteins were puriﬁed by passing the extracts through
a 1-ml bed volume of glutathione-Sepharose columns (BioRad).
GST-Glc7was eluted from the column with 10 mM glutathione.
Samples were stored at 80 C.
2.6. Expression of recombinant proteins in HEK293T cells
HEK293T cells were seeded in p150 plates. When the cells
reached conﬂuence, they were transfected with 50 lg/plate of
pcDNA3-FLAG-PP1. On the ﬁrst day post-transfection, we replaced
the medium by fresh Dulbecco’s Modiﬁed Eagle’s Medium (DMEM,
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serum (FBS). On the second day post-transfection, cell culture
medium was removed, and 500 ll of cold lysis buffer (30 mM
Tris–HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM benzam-
idine, 1 mM phenylmethylsulfonyl ﬂuoride, 25 nM okadaic acid,
10 lg/ml leupeptin, 10 lg/ml aprotinin, and 10 lg/ml pepstatin)
was added per dish. Cells were collected using cell scrapers and
incubated in lysis buffer for 20 min in an orbital shaker at 4 C
and low speed. The extract was then centrifuged for 10 min at
5000g. The supernatant was then collected. Next, 200 ll of
anti-FLAG agarose resin (Sigma) was added to the extract, and it
was incubated overnight at 4 C using an overhead tumbler. The
following day, cell extracts with resin were centrifuged at
1000g and 4 C for 5 min. The resin was transferred to an
Eppendorf tube, in which it was washed once using 500 ll of cold
wash buffer (30 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.1% Nonidet
P-40) and ﬁve times more with TBS. The resin was then incubated
for 10 min with elution buffer (30 mM Tris–HCl pH 7.4, 150 mM
NaCl, 500 lg/ml FLAG peptide), and protein was eluted.2.7. Protein phosphatase assays
Protein phosphatase activity using p-nitrophenylphosphate
(pNPP) as substrate was determined essentially as described [52].
The reaction buffer was 50 mM Tris–HCl pH 7.5, 0.1 mM EGTA,
2 mM MnCl2, and 1 mM dithiothreitol. Samples were incubated
for 10 min at 30 C (Glc7p) or 37 C (PP1), and the reaction was
then stopped by adding 1% Tris (ﬁnal concentration). For phospha-
tase inhibition assays, a range of concentrations of tungstate were
incubated with the puriﬁed phosphatases during 5 min at 30 or
37 C, prior to the addition of pNPP.3. Results
3.1. Tungstate relieves the growth defect caused by FK506-induced
amino acid deprivation
We tested the tungstate effects on the yeast cell growth defect
caused by FK506-induced amino acid deprivation. We used theWT
w303.1a strain and the Dcnb1 mutant. In the latter, the calcineurin
regulatory subunit CNB1, a therapeutic FK506 target, is absent [53].
Tungstate restored cell growth in the FK506-treated yeast cells
(Fig. 1A), indicating that tungstate somehow alleviated the amino
acid deprivation caused by FK506 treatment.3.2. Tungstate enhances FK506-dependent GCN pathway activation
FK506 activates the GCN pathway and stimulates GCN4 selec-
tive translation, via Gcn2p kinase [7]. In order to identify the
effects of tungstate on translational control, we studied the activa-
tion of the GCN pathway in presence/absence of tungstate.
Tungstate alone did not induce expression of a GCN4-lacZ reporter
in the WT strain. Interestingly, tungstate greatly enhanced
FK506-dependent GCN4-lacZ reporter induction in a dose-depen-
dent manner (Fig. 1B). Tungstate also stimulated a HIS4-lacZ
p377 reporter activation by FK506 (Fig. 1C). We also monitored
the phosphorylation status of the sole Gcn2p kinase substrate in
yeast, the a subunit of the eukaryotic initiation factor 2 (eIF2a)
by immunodetection with a phospho-eIF2a speciﬁc antibody. As
expected, tungstate incremented the FK506-induced amount of
phospho-eIF2a (Fig. 1D). Taken together, these data indicated that
tungstate treatment enhanced the GCN pathway activation by
FK506 in yeast.3.3. Tungstate overcomes 3-aminotriazole sensitivity of a
hypomorphic GCN2 mutant
Glc7p is the yeast orthologue of PP1 [29] which negatively reg-
ulates GCN4 translation through eIF2a dephosphorylation [28]. Gi-
ven that tungstate is considered to be a phosphatase inhibitor,
Glc7p inhibition by the compound could potentially exert its ef-
fects on the GCN pathway. To test whether tungstate inhibits
in vivo the Glc7p phosphatase, we evaluated the effect of the agent
on growth of the hypomorphic gcn2-507 mutant under starvation
conditions. This mutant exhibits constitutively low Gcn2p kinase
activity and, consequently, reduced derepression of the Gcn4p-reg-
ulated genes in response to starvation. This set of strains is proto-
troph for tryptophan, so we induced histidine deprivation with
3AT, instead of FK506, who mainly causes defects in tryptophan
uptake. The gcn2-507 mutant grows slowly in the presence of
3AT concentrations that are lethal for a Dgcn2 strain. In the gcn2-
507 strain, eIF2a phosphorylation is defective, but the inhibition
of Glc7p by overexpression of a dominant-negative Glc7p mutant
can increase it sufﬁciently to overcome 3AT toxicity [28]. As shown
on Fig. 2A, tungstate increased the tolerance of the WT and gcn2-
507 strains to 3AT, to the same extent as the Glc7p dominant neg-
ative expression. Furthermore, tungstate signiﬁcantly enhanced
the yeast 3AT tolerance induced by expression of the Glc7p domi-
nant negative (Fig. 2A). Overall, these data are consistent with
Glc7p as a mediator of tungstate effects in yeast.
3.4. A mutant with low Glc7p activity mimics tungstate-induced
effects
If Glc7p inhibition contributes to the tungstate phenotype in
yeast, a strain without Glc7p activity should mimic the effects of
tungstate. As GLC7 is an essential gene, in thew303.1a genetic back-
groundwe used the plasmid p27-1, overexpressing a truncated ver-
sion of the phosphatase that behaves as a negative dominant, thus
yielding undetectable Glc7p activity [28]. For this purpose, we grew
the strains in plates with/without FK506 (50 lg/ml) and treated or
not with tungstate (10 mM). TheWT p27-1 strain partially relieved
FK506 toxicity in yeast (Fig. 2B). We also analyzed the activation of
the HIS4-lacZ p377 reporter in the same strains (YEp24 and p27-1)
under the same conditions. As expected, FK506-dependent HIS4-
lacZ p377 reporter activation was signiﬁcantly higher in the p27-
1 strain than that of the control YEp24 strain (Fig. 2C), thus resem-
bling tungstate effects on reporter activation. Interestingly, tung-
state did not increase p377 induction in the p27-1 strain. Taken
together, these data indicate that Glc7p inhibition mimics the ef-
fects of tungstate in yeast.
3.5. Tungstate inhibits yeast and human PP1 in vitro
To give further support to our hypothesis, we used a recombi-
nant fusion protein Glc7p-GST as well as a fusion human PP1-FLAG
and tested the effect of tungstate on phosphatase assays. Tungstate
inhibited Glc7p activity with an IC50 around 1 mM, value that is in
the pharmacological range (Fig. 2D). This compound also inhibited
human PP1 activity with an IC50 similar to that observed with
Glc7p (Fig. 2E). Therefore, Glc7p inhibition might mediate tung-
state-induced effects in yeast.
4. Discussion
Here we report that the anti-diabetic and anti-obesity agent
sodium tungstate enhanced the activation of the GCN pathway in
budding yeast. This behavior involved inhibition of Glc7p
phosphatase, as a dominant negative of this enzyme mutant mim-
Fig. 1. Tungstate rescues the growth defect caused by FK506 and enhances FK506-dependent GCN pathway activation. (A) Growth of theWT (W303.1a) and Dcnb1 strains on
YPD plates containing FK506 (50 lg/ml) and/or sodium tungstate (10 mM). (B) Dose-dependent induction of the p180 GCN4-LacZ reporter in a WT strain exposed to
increasing concentrations of sodium tungstate and treated or not with the pathway activator FK506 (50 lg/ml). (C) Induction of the p377 HIS4-LacZ reporter in WT strain
treated or not with FK506 (50 lg/ml) plus or minus 10 mM sodium tungstate. (D) Immunodetection of phospho-eIF2a (P-eIF2a) in the WT strain treated with FK506 (50 lg/
ml) plus or minus 10 mM sodium tungstate at the indicated times. Even loading of the gels was conﬁrmed by Ponceau S (PonS) staining of membranes after transfer.
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at pharmacologically relevant doses. These ﬁndings support the no-
tion that Glc7p might be the target of tungstate effects in yeast.
The simplest explanation for the observed tungstate-induced
phenotypes is that the drug modulates the status of eIF2a phos-
phorylation in the cell. This modulation seems to be independent
of Gcn2p, as the 3AT sensitivity of the hypomorphic gcn2-507 mu-
tant was alleviated by tungstate. Therefore, eIF2a phosphatases are
good candidates for mediating tungstate effects. Accordingly, a
mutant with low Glc7p activity was partially resistant to FK506
(Fig. 2B) and to GCN pathway regulation by tungstate (Fig. 2C).
Tungstate-dependent inhibition of Glc7p and its mammalian
orthologue PP1 in vitro indicates that suppression might occur di-
rectly on the catalytic activity of the enzyme. However, we cannot
exclude the involvement of Glc7p regulatory subunits, as tungstate
has been described to inhibit the interaction between Cdc14p and
its regulator Net1p [54].
Tungstate exerts anti-diabetic effects in many experimental
models. It potentiates insulin effects in rat adipocytes [55,56],stimulates insulin release in rat pancreas [57], favors b-cell regen-
eration in rat pancreas [58] and is an efﬁcient oral anti-diabetic
agent in Zucker fatty [44] and streptozotocin-induced [41,42] dia-
betic rats. In the latter model this compound also improves other
parameters, such as cardiac [59] and reproductive [60] functions,
and alleviates oxidative stress in brain [61]. However, most of
the mechanisms underlying these effects are unknown. Our data
obtained with yeast suggest that PP1 phosphatase could be a
potential candidate target for tungstate action. Several pharmaco-
logical studies have revealed the relevance of PP1 in insulin-depen-
dent regulation of metabolic enzymes such as glycogen synthase,
hormone-sensitive lipase and acetyl-CoA carboxylase [62,63].
Furthermore, many studies have reported the importance of eIF2a
kinases in diabetic syndromes [18–20], hyperglycemia, and b-cell
death in mice [21,22] and also in the translational control of insulin
mRNA [23]. Nevertheless, taken into account the high range of
potential phosphatase inhibition by tungstate in vivo [36–39], we
cannot rule out the possibility of phosphatases other than Glc7p/
PP1 contributing to the cellular effects of this compound.
Fig. 2. Inhibition of Glc7p phosphatase is consistent with tungstate-induced effects. (A) Growth of H1402 strains (WT, Dgcn2 and gcn2-507) transformed with empty vector
(YEp24) or a plasmid carrying a Glc7p dominant negative (p27-1) on SD plates containing 12,5 mM 3-amino-1,2,4-triazole and/or sodium tungstate (10 mM). (B) Growth of a
w303.1a WT strain expressing either a Glc7p dominant negative (p27-1) or empty vector (YEp24) on YPD plates containing FK506 (50 lg/ml) and/or sodium tungstate
(10 mM). (C) Induction of the p377 HIS4-LacZ reporter in w303.1a YEp24 and p27-1 strains treated with FK506 (50 lg/ml) in the presence or absence of 10 mM sodium
tungstate. Protein phosphatase activity using p-nitrophenylphosphate as substrate in the presence of increasing concentrations of sodium tungstate: (D) yeast Glc7p
expressed in E. coli and puriﬁed as explained in Section 2; and (E) human PP1, expressed in and puriﬁed from HEK293T cells as explained in Section 2. IC50 data were
calculated with Sigma-Plot software (Systat Software, Inc.).
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that the interaction between FK506 and tungstate could be of ther-
apeutic signiﬁcance. One of the most important side effects of
FK506 immunosuppression is post-transplantation diabetes melli-
tus (PTDM). Therefore, tungstate could be used to alleviate the
adverse side effects of FK506. This hypothesis is currently being
tested in a rat model of FK506-induced diabetes.
Furthermore, given the strong link between eIF2a phoshoryla-
tion and human disease, our ﬁndings suggest that the therapeutic
use of tungstate could be relevant for treating other pathologies
involving eIF2a phosphorylation such as (1) tumoral processes[64,65], (2) viral infections (reviewed in [66]), (3) organ preserva-
tion [67] and (4) sleep disorders [68]. Testing the effects of tung-
state in cellular/animal models of these diseases would
undoubtfully expand the applications of sodium tungstate in
chemotherapy.
Acknowledgements
We thank R. Serrano for providing the Dcnb1mutant strain. We
thank A. G. Hinnebusch for the gcn2-507 and gcn2 mutant strains.
The pGEX-GLC7 plasmid was kindly provided by P. Sanz. The
C.J. Rodriguez-Hernandez et al. / FEBS Letters 586 (2012) 270–276 275PP1-FLAG construct was kindly provided by A.C. Gingras. We thank
T. Yates and J. Calbo for critical reading of the manuscript and
helpful suggestions. J.J. Guinovart’s laboratory was funded by
grants from the Dirección General de Investigación Cientíﬁca y
Técnica (BFU2008-00769), the Generalitat de Catalunya (2009
SGR 01176), the Fundación Marcelino Botín and the CIBER de
Diabetes y Enfermedades Metabólicas Asociadas (ISCIII, Ministerio
de Ciencia e Innovación). J.R. Murguia laboratory was funded by
Fondo de Investigaciones Sanitarias (FIS03-0628).
References
[1] Berlanga, J.J., Santoyo, J. and De Haro, C. (1999) Characterization of a
mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase.
Eur. J. Biochem. 265, 754–762.
[2] Hinnebusch, A.G. (1997) Translational regulation of yeast GCN4. A window on
factors that control initiator-tRNA binding to the ribosome. J. Biol. Chem. 272,
21661–21664.
[3] Natarajan, K., Meyer, M.R., Jackson, B.M., Slade, D., Roberts, C., Hinnebusch,
A.G. and Marton, M.J. (2001) Transcriptional proﬁling shows that Gcn4p is a
master regulator of gene expression during amino acid starvation in yeast.
Mol. Cell. Biol. 21, 4347–4368.
[4] Dumont, F.J. (2000) FK506, an immunosuppressant targeting calcineurin
function. Curr. Med. Chem. 7, 731–748.
[5] Heitman, J., Koller, A., Kunz, J., Henriquez, R., Schmidt, A., Movva, N.R. and Hall,
M.N. (1993) The immunosuppressant FK506 inhibits amino acid import in
Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 5010–5019.
[6] Schmidt, A., Hall, M.N. and Koller, A. (1994) Two FK506 resistance-conferring
genes in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid
permeases mediating tyrosine and tryptophan uptake. Mol. Cell. Biol. 14,
6597–6606.
[7] Rodriguez-Hernandez, C.J., Sanchez-Perez, I., Gil-Mascarell, R., Rodriguez-
Afonso, A., Torres, A., Perona, R. and Murguia, J.R. (2003) The
immunosuppressant FK506 uncovers a positive regulatory cross-talk
between the Hog1p and Gcn2p pathways. J. Biol. Chem. 278, 33887–33895.
[8] Penn, M.D., Galgoci, B. and Greer, H. (1983) Identiﬁcation of AAS genes and
their regulatory role in general control of amino acid biosynthesis in yeast.
Proc. Natl. Acad. Sci. USA 80, 2704–2708.
[9] Rolfes, R.J. and Hinnebusch, A.G. (1993) Translation of the yeast transcriptional
activator GCN4 is stimulated by purine limitation: implications for activation
of the protein kinase GCN2. Mol. Cell. Biol. 13, 5099–5111.
[10] Yang, R., Wek, S.A. and Wek, R.C. (2000) Glucose limitation induces GCN4
translation by activation of Gcn2 protein kinase. Mol. Cell. Biol. 20, 2706–2717.
[11] Goossens, A., Dever, T.E., Pascual-Ahuir, A. and Serrano, R. (2001) The protein
kinase Gcn2p mediates sodium toxicity in yeast. J. Biol. Chem. 276,
30753–30760.
[12] Narasimhan, J., Staschke, K.A. and Wek, R.C. (2004) Dimerization is required
for activation of eIF2 kinase Gcn2 in response to diverse environmental stress
conditions. J. Biol. Chem. 279, 22820–22832.
[13] Cherkasova, V.A. and Hinnebusch, A.G. (2003) Translational control by TOR
and TAP42 through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev.
17, 859–872.
[14] Kubota, H., Obata, T., Ota, K., Sasaki, T. and Ito, T. (2003) Rapamycin-induced
translational derepression of GCN4 mRNA involves a novel mechanism for
activation of the eIF2 alpha kinase GCN2. J. Biol. Chem. 278, 20457–
20460.
[15] Valenzuela, L., Aranda, C. and Gonzalez, A. (2001) TOR modulates GCN4-
dependent expression of genes turned on by nitrogen limitation. J. Bacteriol.
183, 2331–2334.
[16] Palmer, L.K., Shoemaker, J.L., Baptiste, B.A., Wolfe, D. and Keil, R.L. (2005)
Inhibition of translation initiation by volatile anesthetics involves nutrient-
sensitive GCN-independent and -dependent processes in yeast. Mol. Biol. Cell
16, 3727–3739.
[17] Wek, R.C., Jiang, H.Y. and Anthony, T.G. (2006) Coping with stress: eIF2 kinases
and translational control. Biochem. Soc. Trans. 34, 7–11.
[18] Wolcott, C.D. and Rallison, M.L. (1972) Infancy-onset diabetes mellitus and
multiple epiphyseal dysplasia. J. Pediatr. 80, 292–297.
[19] Stoss, H., Pesch, H.J., Pontz, B., Otten, A. and Spranger, J. (1982) Wolcott-
Rallison syndrome: diabetes mellitus and spondyloepiphyseal dysplasia. Eur.
J. Pediatr. 138, 120–129.
[20] Delepine, M., Nicolino, M., Barrett, T., Golamaully, M., Lathrop, G.M. and Julier,
C. (2000) EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is
mutated in patients withWolcott-Rallison syndrome. Nat. Genet. 25, 406–409.
[21] Harding, H.P., Zeng, H., Zhang, Y., Jungries, R., Chung, P., Plesken, H., Sabatini,
D.D. and Ron, D. (2001) Diabetes mellitus and exocrine pancreatic dysfunction
in perk/ mice reveals a role for translational control in secretory cell
survival. Mol. Cell 7, 1153–1163.
[22] Scheuner, D. et al. (2001) Translational control is required for the unfolded
protein response and in vivo glucose homeostasis. Mol. Cell 7, 1165–1176.
[23] Scheuner, D. et al. (2005) Control of mRNA translation preserves endoplasmic
reticulum function in beta cells and maintains glucose homeostasis. Nat. Med.
11, 757–764.[24] Ma, Y. and Hendershot, L.M. (2004) The role of the unfolded protein response
in tumour development: friend or foe? Nat. Rev. Cancer 4, 966–977.
[25] Boot-Handford, R.P. and Briggs, M.D. (2010) The unfolded protein response
and its relevance to connective tissue diseases. Cell Tissue Res 339, 197–211.
[26] Rzymski, T., Milani, M., Singleton, D.C. and Harris, A.L. (2009) Role of ATF4 in
regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8,
3838–3847.
[27] Naidoo, N. (2009) Cellular stress/the unfolded protein response: relevance to
sleep and sleep disorders. Sleep Med. Rev. 13, 195–204.
[28] Wek, R.C., Cannon, J.F., Dever, T.E. and Hinnebusch, A.G. (1992) Truncated
protein phosphatase GLC7 restores translational activation of GCN4 expression
in yeast mutants defective for the eIF-2 alpha kinase GCN2. Mol. Cell. Biol. 12,
5700–5710.
[29] Feng, Z.H., Wilson, S.E., Peng, Z.Y., Schlender, K.K., Reimann, E.M. and Trumbly,
R.J. (1991) The yeast GLC7 gene required for glycogen accumulation encodes a
type 1 protein phosphatase. J. Biol. Chem. 266, 23796–23801.
[30] Hisamoto, N., Sugimoto, K. and Matsumoto, K. (1994) The Glc7 type 1 protein
phosphatase of Saccharomyces cerevisiae is required for cell cycle progression
in G2/M. Mol. Cell. Biol. 14, 3158–3165.
[31] Cannon, J.F., Pringle, J.R., Fiechter, A. and Khalil, M. (1994) Characterization of
glycogen-deﬁcient glc mutants of Saccharomyces cerevisiae. Genetics 136,
485–503.
[32] Tu, J. and Carlson, M. (1994) The GLC7 type 1 protein phosphatase is required
for glucose repression in Saccharomyces cerevisiae. Mol. Cell. Biol. 14, 6789–
6796.
[33] Williams-Hart, T., Wu, X. and Tatchell, K. (2002) Protein phosphatase type 1
regulates ion homeostasis in Saccharomyces cerevisiae. Genetics 160, 1423–
1437.
[34] Bazzi, M., Mantiero, D., Trovesi, C., Lucchini, G. and Longhese, M.P. (2010)
Dephosphorylation of gamma H2A by Glc7/protein phosphatase 1 promotes
recovery from inhibition of DNA replication. Mol. Cell Biol 30, 131–145.
[35] Ceulemans, H. and Bollen, M. (2004) Functional diversity of protein
phosphatase-1, a cellular economizer and reset button. Physiol. Rev. 84, 1–39.
[36] Egloff, M.P., Cohen, P.T., Reinemer, P. and Barford, D. (1995) Crystal structure
of the catalytic subunit of human protein phosphatase 1 and its complex with
tungstate. J. Mol. Biol. 254, 942–959.
[37] Fauman, E.B., Yuvaniyama, C., Schubert, H.L., Stuckey, J.A. and Saper, M.A.
(1996) The X-ray crystal structures of Yersinia tyrosine phosphatase with
bound tungstate and nitrate. Mechanistic implications. J. Biol. Chem. 271,
18780–18788.
[38] Foster, J.D., Young, S.E., Brandt, T.D. and Nordlie, R.C. (1998) Tungstate: a
potent inhibitor of multifunctional glucose-6-phosphatase. Arch. Biochem.
Biophys. 354, 125–132.
[39] Stuckey, J.A., Schubert, H.L., Fauman, E.B., Zhang, Z.Y., Dixon, J.E. and Saper,
M.A. (1994) Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A
and the complex with tungstate. Nature 370, 571–575.
[40] Domingo, J.L. (2002) Vanadium and tungsten derivatives as antidiabetic
agents: a review of their toxic effects. Biol. Trace Elem. Res. 88, 97–112.
[41] Barbera, A., Gomis, R.R., Prats, N., Rodriguez-Gil, J.E., Domingo, M., Gomis, R.
and Guinovart, J.J. (2001) Tungstate is an effective antidiabetic agent in
streptozotocin-induced diabetic rats: a long-term study. Diabetologia 44,
507–513.
[42] Barbera, A., Fernandez-Alvarez, J., Truc, A., Gomis, R. and Guinovart, J.J. (1997)
Effects of tungstate in neonatally streptozotocin-induced diabetic rats:
mechanism leading to normalization of glycaemia. Diabetologia 40, 143–149.
[43] Barbera, A., Rodriguez-Gil, J.E. and Guinovart, J.J. (1994) Insulin-like actions of
tungstate in diabetic rats. Normalization of hepatic glucose metabolism. J.
Biol. Chem. 269, 20047–20053.
[44] Munoz, M.C., Barbera, A., Dominguez, J., Fernandez-Alvarez, J., Gomis, R. and
Guinovart, J.J. (2001) Effects of tungstate, a new potential oral antidiabetic
agent, in Zucker diabetic fatty rats. Diabetes 50, 131–138.
[45] Giron, M.D., Caballero, J.J., Vargas, A.M., Suarez, M.D., Guinovart, J.J. and Salto,
R. (2003) Modulation of glucose transporters in rat diaphragm by sodium
tungstate. FEBS Lett. 542, 84–88.
[46] Rodriguez-Gallardo, J., Silvestre, R.A., Egido, E.M. and Marco, J. (2000) Effects of
sodium tungstate on insulin and glucagon secretion in the perfused rat
pancreas. Eur. J. Pharmacol. 402, 199–204.
[47] Claret, M., Corominola, H., Canals, I., Saura, J., Barcelo-Batllori, S., Guinovart, J.J.
and Gomis, R. (2005) Tungstate decreases weight gain and adiposity in obese
rats through increased thermogenesis and lipid oxidation. Endocrinology 146,
4362–4369.
[48] Gietz, R.D., Schiestl, R.H., Willems, A.R. and Woods, R.A. (1995) Studies on the
transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast
11, 355–360.
[49] Pinson, B., Sagot, I., Borne, F., Gabrielsen, O.S. and Daignan-Fornier, B. (1998)
Mutations in the yeast Myb-like protein Bas1p resulting in discrimination
between promoters in vivo but not in vitro. Nucleic Acids Res. 26, 3977–3985.
[50] Prinz, W. (2003) Methods in enzymology (Guthrie, Christine and Fink, Gerald,
Eds.), Guide to Yeast Genetics and Molecular and Cell Biology, Parts B and C,
vols. 350 and 351, pp. 289–290, Academic Press, New York.
[51] Gaxiola, R., de Larrinoa, I.F., Villalba, J.M. and Serrano, R. (1992) A novel and
conserved salt-induced protein is an important determinant of salt tolerance
in yeast. EMBO J. 11, 3157–3164.
[52] Silberman, S.R., Speth, M., Nemani, R., Ganapathi, M.K., Dombradi, V., Paris, H.
and Lee, E.Y. (1984) Isolation and characterization of rabbit skeletal muscle
protein phosphatases C-I and C-II. J. Biol. Chem. 259, 2913–2922.
276 C.J. Rodriguez-Hernandez et al. / FEBS Letters 586 (2012) 270–276[53] Ferrando, A., Kron, S.J., Rios, G., Fink, G.R. and Serrano, R. (1995) Regulation of
cation transport in Saccharomyces cerevisiae by the salt tolerance gene HAL3.
Mol. Cell. Biol. 15, 5470–5481.
[54] Traverso, E.E., Baskerville, C., Liu, Y., Shou, W., James, P., Deshaies, R.J. and
Charbonneau, H. (2001) Characterization of the Net1 cell cycle-dependent
regulator of the Cdc14 phosphatase from budding yeast. J. Biol. Chem. 276,
21924–21931.
[55] Goto, Y. and Kida, K. (1995) Insulin-like action of chromate on glucose
transport in isolated rat adipocytes. Jpn. J. Pharmacol. 67, 365–368.
[56] Li, J., Elberg, G., Gefel, D. and Shechter, Y. (1995) Permolybdate and
pertungstate – potent stimulators of insulin effects in rat adipocytes:
mechanism of action. Biochemistry 34, 6218–6225.
[57] Silvestre, R.A., Egido, E.M., Hernandez, R. and Marco, J. (2005) Tungstate
stimulates insulin release and inhibits somatostatin output in the perfused rat
pancreas. Eur. J. Pharmacol. 519, 127–134.
[58] Fernandez-Alvarez, J., Barbera, A., Nadal, B., Barcelo-Batllori, S., Piquer, S.,
Claret, M., Guinovart, J.J. and Gomis, R. (2004) Stable and functional
regeneration of pancreatic beta-cell population in nSTZ-rats treated with
tungstate. Diabetologia 47, 470–477.
[59] Nagareddy, P.R., Vasudevan, H. and McNeill, J.H. (2005) Oral administration of
sodium tungstate improves cardiac performance in streptozotocin-induced
diabetic rats. Can. J. Physiol. Pharmacol. 83, 405–411.
[60] Ballester, J., Dominguez, J., Munoz, M.C., Sensat, M., Rigau, T., Guinovart, J.J. and
Rodriguez-Gil, J.E. (2005) Tungstate treatment improves Leydig cell function
in streptozotocin-diabetic rats. J. Androl. 26, 706–715.[61] Nakhaee, A., Bokaeian, M., Akbarzadeh, A. and Hashemi, M. (2009) Sodium
tungstate attenuate oxidative stress in brain tissue of streptozotocin-induced
diabetic rats. Biol Trace Elem Res 136, 221–231.
[62] Haystead, T.A., Sim, A.T., Carling, D., Honnor, R.C., Tsukitani, Y., Cohen, P.
and Hardie, D.G. (1989) Effects of the tumour promoter okadaic acid on
intracellular protein phosphorylation and metabolism. Nature 337,
78–81.
[63] Hess, S.L., Suchin, C.R. and Saltiel, A.R. (1991) The speciﬁc protein phosphatase
inhibitor okadaic acid differentially modulates insulin action. J. Cell. Biochem.
45, 374–380.
[64] Jiang, H.Y. and Wek, R.C. (2005) Phosphorylation of the alpha-subunit of the
eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and
enhances apoptosis in response to proteasome inhibition. J. Biol. Chem. 280,
14189–14202.
[65] Perkins, D.J. and Barber, G.N. (2004) Defects in translational regulation
mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit
antiviral activity and facilitate the malignant transformation of human
ﬁbroblasts. Mol. Cell. Biol. 24, 2025–2040.
[66] Kaempfer, R. (2003) RNA sensors: novel regulators of gene expression. EMBO
Rep. 4, 1043–1047.
[67] Lu, P.D. et al. (2004) Cytoprotection by pre-emptive conditional
phosphorylation of translation initiation factor 2. EMBO J. 23, 169–179.
[68] Naidoo, N., Ferber, M., Master, M., Zhu, Y. and Pack, A.I. (2008) Aging impairs
the unfolded protein response to sleep deprivation and leads to proapoptotic
signaling. J. Neurosci. 28, 6539–6548.
